CRISPR/dCas9-based activation systems (CRISPRa) enable sequence-specific gene activation and are therefore of particular interest for the 'shock and kill' cure approach against HIV-1 infections. This approach aims to activate the latent HIV-1 proviruses in infected cells and subsequently kill these cells. Several CRISPRa systems have been shown to specifically and effectively activate latent HIV-1 when targeted to the HIV-1 5'LTR promoter, making them a promising 'shock' strategy. Here, we aimed to evaluate the dCas9-VPR system for its applicability in reversing HIV-1 latency and identify the optimal gRNA target site in the HIV-1 5'LTR promoter leading to the strongest activation of the provirus with this system. We systematically screened ...
Objectives: The long-term goal of our study is to inactivate the HIV-1 genome integrated into the ch...
The presence of latently infected cells and reservoirs in HIV-1 infected patients constitutes a sign...
Once infected with HIV-1, the host immune system is incapable of ridding itself of the virus. HIV-1 ...
CRISPR/dCas9-based activation systems (CRISPRa) enable sequence-specific gene activation and are the...
HIV-1 provirus integration results in a persistent latently infected reservoir that is recalcitrant ...
Complete eradication of HIV-1 infection is impeded by the existence of cells that harbor chromosomal...
<div><p>CRISPR/Cas9 technology is currently considered the most advanced tool for targeted genome en...
The CRISPR/Cas9 gene editing method is comprised of the guide RNA (gRNA) to target a specific DNA se...
HIV presents one of the highest evolutionary rates ever detected and combination antiretroviral ther...
Eradicating HIV-1 from an infected individual remains one of the main quests in HIV-1 research. Howe...
Current combined antiretroviral therapy (cART) can effectively reduce the viral load in patients to ...
To counter HIV latency, it is important to develop a better understanding of the full range of host ...
Novel therapeutic strategies aiming at the permanent inactivation of the HIV-1 reservoir in infected...
Novel therapeutic strategies aiming at the permanent inactivation of the HIV-1 reservoir in infected...
The presence of latently infected cells and reservoirs in HIV-1 infected patients constitutes a sign...
Objectives: The long-term goal of our study is to inactivate the HIV-1 genome integrated into the ch...
The presence of latently infected cells and reservoirs in HIV-1 infected patients constitutes a sign...
Once infected with HIV-1, the host immune system is incapable of ridding itself of the virus. HIV-1 ...
CRISPR/dCas9-based activation systems (CRISPRa) enable sequence-specific gene activation and are the...
HIV-1 provirus integration results in a persistent latently infected reservoir that is recalcitrant ...
Complete eradication of HIV-1 infection is impeded by the existence of cells that harbor chromosomal...
<div><p>CRISPR/Cas9 technology is currently considered the most advanced tool for targeted genome en...
The CRISPR/Cas9 gene editing method is comprised of the guide RNA (gRNA) to target a specific DNA se...
HIV presents one of the highest evolutionary rates ever detected and combination antiretroviral ther...
Eradicating HIV-1 from an infected individual remains one of the main quests in HIV-1 research. Howe...
Current combined antiretroviral therapy (cART) can effectively reduce the viral load in patients to ...
To counter HIV latency, it is important to develop a better understanding of the full range of host ...
Novel therapeutic strategies aiming at the permanent inactivation of the HIV-1 reservoir in infected...
Novel therapeutic strategies aiming at the permanent inactivation of the HIV-1 reservoir in infected...
The presence of latently infected cells and reservoirs in HIV-1 infected patients constitutes a sign...
Objectives: The long-term goal of our study is to inactivate the HIV-1 genome integrated into the ch...
The presence of latently infected cells and reservoirs in HIV-1 infected patients constitutes a sign...
Once infected with HIV-1, the host immune system is incapable of ridding itself of the virus. HIV-1 ...